Valuation: Arvinas, Inc.

Market Cap 50Cr 45Cr 41Cr 37Cr 69Cr 4.73TCr 70Cr 492.23Cr 196.11Cr 2.48TCr 186.42Cr 182.52Cr 7.84TCr P/E 2026 *
-338x
P/E 2027 * -2.18x
Enterprise Value 4.62Cr 4.14Cr 3.82Cr 3.47Cr 6.46Cr 439.82Cr 6.55Cr 46Cr 18Cr 230.18Cr 17Cr 17Cr 728.52Cr EV / Sales 2026 *
0.16x
EV / Sales 2027 * 2.96x
Free-Float
79.97%
Yield 2026 *
-
Yield 2027 * -
1 day+2.01%
1 week+0.60%
Current month-1.75%
1 month+1.20%
3 months-7.32%
6 months-25.64%
Current year-35.92%
1 week 7.2
Extreme 7.2
7.7
1 month 6.74
Extreme 6.74
8.04
Current year 6.74
Extreme 6.74
14.51
1 year 6.74
Extreme 6.74
14.51
3 years 5.9
Extreme 5.9
53.08
5 years 5.9
Extreme 5.9
97.33
10 years 5.9
Extreme 5.9
108.46
Manager TitleAgeSince
Chief Executive Officer 47 12/02/2026
Director of Finance/CFO 56 24/06/2024
Chief Tech/Sci/R&D Officer 58 17/06/2024
Director TitleAgeSince
Chairman 66 15/06/2023
Director/Board Member 65 01/07/2018
Chairman 67 12/02/2026
Date Insider Type Main position Quantity % Market Cap. Importance
21/05/26 Sell

Chief Executive Officer

-2,209 0.0035%
11/05/26 Sell

Chief Financial Officer

-11,139 0.0174%
11/05/26 Sell

Chief Technology Officer

-11,108 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
+2.01%+0.60%-20.00%-46.44% 49Cr
+0.65%-3.56%+33.53%+60.50% 6.35TCr
+1.76%+1.27%+11.82%+81.21% 5.45TCr
-0.94%+0.77%+8.85%+100.19% 5.36TCr
+2.76%+0.87%+27.92%+55.07% 4.48TCr
+2.00%-3.39%+17.83%+119.04% 4.16TCr
+1.34%-2.86%+224.43%+914.08% 3.99TCr
+0.64%-3.85%+11.71%+45.57% 3.25TCr
+29.06%+48.65%+106.84%+92.73% 2.67TCr
+3.72%-7.45%+24.25%-2.99% 2.34TCr
Average +4.30%-0.65%+44.72%+141.90% 3.81TCr
Weighted average by Cap. +3.23%-0.29%+47.22%+161.20%

Financials

2026 *2027 *
Net sales 30Cr 27Cr 25Cr 22Cr 41Cr 2.82TCr 42Cr 293.3Cr 116.85Cr 1.48TCr 111.08Cr 108.76Cr 4.67TCr 6.42Cr 5.75Cr 5.31Cr 4.82Cr 8.98Cr 611.18Cr 9.1Cr 64Cr 25Cr 319.87Cr 24Cr 24Cr 1.01TCr
Net income -7L -6L -6L -5L -9L -6.34Cr -9L -66.01L -26.3L -3.32Cr -25L -24.48L -11Cr -25Cr -22Cr -21Cr -19Cr -35Cr -2.36TCr -35Cr -245.5Cr -98Cr -1.24TCr -93Cr -91Cr -3.91TCr
Net Debt -45Cr -40Cr -37Cr -34Cr -63Cr -4.29TCr -64Cr -446.47Cr -177.88Cr -2.25TCr -169.09Cr -165.55Cr -7.11TCr -31Cr -27Cr -25Cr -23Cr -43Cr -2.92TCr -44Cr -303.92Cr -121.09Cr -1.53TCr -115.1Cr -112.69Cr -4.84TCr
Projected Income Statement - Annual - Arvinas, Inc.
Logo Arvinas, Inc.
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Employees
246
Date Price Change Volume
28/26/28 $7.600 +2.01% 8,89,804
27/26/27 $7.450 +1.92% 8,00,824
26/26/26 $7.310 +0.14% 7,24,861
23/26/23 $7.300 -5.44% 6,51,573
22/26/22 $7.720 +2.18% 6,20,196
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Arvinas, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
7.600USD
Average target price
13.93USD
Spread / Average Target
+83.27%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Arvinas, Inc.
  1. Stock Market
  2. Stocks
  3. ARVN Stock